Evidence map›Paper›PMID 38983115›Full record

ArticleFrontiers in cellular and infection microbiology2024

Implications of silver nanoparticles for

Lucie Hochvaldova, Gernot Posselt, Silja Wessler, Libor Kvítek, Aleš Panáček

Abstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Eco-Friendly Synthesis and Characterization ofPharmaceuticals (Basel, Switzerland) · 2026
    Article
  3. Review
  4. Article
  5. RSC advances · 2025
    Review
  6. Optimization ofInternational journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lucie HochvaldovaDepartment of Physical Chemistry, Palacky University Olomouc, Olomouc, Czechia.
Gernot PosseltDepartment of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Salzburg, Austria.
Silja WesslerDepartment of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Salzburg, Austria.
Libor KvítekDepartment of Physical Chemistry, Palacky University Olomouc, Olomouc, Czechia.
Aleš PanáčekDepartment of Physical Chemistry, Palacky University Olomouc, Olomouc, Czechia.

Funding

Austrian Science Fund FWF I 4360Austrian Science Fund FWF P 31507
6 · The paper itself

Abstract

Background: Helicobacter pylori infection poses a significant health burden worldwide, and its virulence factor CagA plays a pivotal role in its pathogenesis. Methods: In this study, the interaction between H. pylori-infected AGS cells and silver nanoparticles (AgNPs) was investigated, with a focus on the modulation of CagA-mediated responses, investigated by western blotting. Both, the dose-dependent efficacy against H. pylori (growth curves, CFU assay) and the impact of the nanoparticles on AGS cells (MTT assay) were elucidated. Results: AGS cells infected with H. pylori displayed dramatic morphological changes, characterized by elongation and a migratory phenotype, attributed to CagA activity. Preincubation of H. pylori with AgNPs affected these morphological changes in a concentration-dependent manner, suggesting a correlation between AgNPs concentration and CagA function. Conclusion: Our study highlights the nuanced interplay between host-pathogen interactions and the therapeutic potential of AgNPs in combating H. pylori infection and offers valuable insights into the multifaceted dynamics of CagA mediated responses.

Indexed as

Antigens, BacterialBacterial ProteinsHelicobacter InfectionsHelicobacter pyloriMetal NanoparticlesSignal TransductionSilverAnti-Bacterial AgentsCell LineCell Line, TumorEpithelial CellsHost-Pathogen InteractionsHumansVirulence FactorsAnti-Bacterial AgentsAntigens, BacterialBacterial ProteinscagA protein, Helicobacter pyloriSilverVirulence FactorsAGSCagAH. pyloriIL-8infectionminimum inhibitory concentrationsilver nanoparticles

Identifiers

PMID38983115
PMCPMC11231068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.